Generic ADP-recognizing nucleotide-binding proteins

Generic ADP-recognizing nucleotide-binding proteins is a broad functional classification encompassing a diverse array of proteins that utilize adenosine diphosphate (ADP) as a ligand, substrate, or allosteric regulator (UniProt, 2024). This group includes critical therapeutic targets such as the P2Y family of G protein-coupled receptors, notably P2Y12, which mediates platelet aggregation and is the target of drugs like clopidogrel and ticagrelor (Burnstock, 2006, British Journal of Pharmacology). Additionally, it covers enzymes involved in ADP-ribosylation, such as poly(ADP-ribose) polymerases (PARPs), which play pivotal roles in DNA repair and are targeted by inhibitors like olaparib in oncology (Lord & Ashworth, 2017, Science). Because this term describes a shared biochemical property—often involving the Walker A motif or P-loop—rather than a single protein, it is not considered a discrete therapeutic target (Walker et al., 1982, EMBO J). Instead, specific members within this class are targeted for various indications, including cardiovascular diseases and various cancers. Consequently, therapeutic effects, safety profiles, and biomarkers are highly dependent on the specific protein member being targeted rather than the class as a whole.

Other names

ADP-binding proteinsAdenosine diphosphate-binding proteinsADP-recognizing proteinsPurinergic receptors (ADP-selective)ADP-ribosyltransferases

Antagonism of purinergic P2Y receptors to inhibit platelet aggregation or inhibition of poly(ADP-ribose) polymerase (PARP) enzymes to prevent DNA repair in susceptible cancer cells.